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Brahm H. Segal,1 Paul Veys,2 Harry Malech,3 Morton J. Cowan4Chronic granulomatous disease (CGD) is a rare primary immunodeficiency with X-linked or autosomal
recessive inheritance involving defects in genes encoding phox proteins, which are the subunits of the phago-
cyte NADPH oxidase. This results in failure to produce superoxide anion and downstream antimicrobial
oxidant metabolites and to activate antimicrobial proteases. Affected patients are susceptible to severe,
life-threatening bacterial and fungal infections and excessive inflammation characterized by granulomatous
enteritis resembling Crohn’s disease and genitourinary obstruction. Early diagnosis of CGD and rapid treat-
ment of infections are critical. Prophylaxis with antibacterial and mold-active antifungal agents and the admin-
istration of interferon-g has significantly improved the natural history of CGD. Currently, the only cure is
allogeneic hematopoietic cell transplant (HCT), although there remains controversy as to which patients
with CGD should get a transplant. Allele-based HLA typing of alternative donors, improved supportive
care measures, and use of reduced toxicity conditioning have resulted in event-free survival (EFS) of at least
80% even with an unrelated donor and even better when the patient has no active infections/inflammation.
Gene correction of CGD would eliminate the risks of graft-versus-host disease (GVHD) and the immunoa-
blative chemotherapy required for allogeneic HCT. Based on gene therapy trials in patients with SCID-X1,
ADA-SCID, and the early experience with CGD, it is clear that at least some degree of myeloablation will
be necessary for CGD as there is no inherent selective growth advantage for gene-corrected cells. Current
efforts for gene therapy focus on use of lentivector constructs, which are thought to be safer from the stand-
point of insertional mutagenesis and more efficient in transducing hematopoietic stem cells (HSCs).
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AND MANAGEMENTOF CHRONIC
GRANULOMATOUS DISEASE
A Disorder of NADPH Oxidase
Chronic granulomatous disease (CGD) is an in-
herited disorder of the NADPH oxidase characterized
by severe bacterial and fungal infections and excessive in-
flammation. CGD affects approximately 1 in 200,000
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6/j.bbmt.2010.09.008a fatal granulomatous disease of childhood. In the
1960s, classic studies linked CGD with impaired
neutrophil bactericidal activity. Neutrophils from
CGD patients failed to show an increase in oxygen con-
sumption and hydrogen peroxide formation. This rapid
oxygen consumption (‘‘respiratory burst’’) was initially
attributed to increased mitochondrial respiration, but
later linked to the NADPH oxidase. CGD was subse-
quently identified as a disorder of NADPH oxidase
activation.
The phagocyte NADPH oxidase functions to
rapidly generate superoxide anion by transferring elec-
trons from NADPH to molecular oxygen (Figure 1).
The cytochrome of NADPH oxidase, composed of
gp91phox (phox, phagocyte oxidase) and p22phox, is em-
bedded in membranes. Upon activation of the oxidase,
the cytoplasmic subunits p47phox, p67phox, and p40phox
appear to translocate en bloc to the membrane-
bound cytochrome. Activation of Rac, a member of
the low molecular weight GTP-binding proteins,
and translocation of Rac to the membrane-bound
cytochrome are also critical for NADPH oxidase acti-
vation. CGD results from disabling mutations in genesS123
Figure 1. NADPH oxidase activation requires translocation of cytosolic phox proteins and Rac to the membrane-bound flavocytochrome. Upon
activation, NADPH is oxidized and electrons are transported to the other side of the membrane where molecular oxygen is converted to superoxide
anion, leading to generation of downstream metabolites, such as hydrogen peroxide and hypohalous acid. In addition to the direct microbicidal
properties of these reactive oxidants, activation of NADPH oxidase in neutrophils is associated with activation of intracellular proteases (eg, neutrophil
elastase, cathepsin G) and release of neutrophil extracellular traps (NETs) that also mediate antimicrobial host defense. SOD, superoxide dismutase;
MPO, myeloperoxidase.
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CGD cases are X-linked (gp91phox-deficient), and the
remainder are autosomal recessive [1].NADPH Oxidase-Mediated Antimicrobial Host
Defense
NADPH oxidase activation results in production of
superoxide anion anddownstreamantimicrobial oxidant
metabolites, such as hydrogen peroxide and hypohalous
acid. Reeves et al. [2] showed that activation of the
NADPH oxidase also leads to the activation of antimi-
crobial proteases sequestered in the primary (azuro-
philic) granules of neutrophils. Activation of these
granular proteases likely enhances killing of pathogens
within phagolysosomes. Neutrophils also release
granule proteins and chromatin that comingle in the ex-
tracellular space and together form neutrophil extracel-
lular traps (NETs). These NETs bind to and kill
extracellular bacteria, degradebacterial virulence factors
[3], and target fungi [4]. Release ofNETs requires death
of neutrophils and breakdown of cell membranes [5].
Neutrophils from CGD patients are deficient in NET
formation [4,5]; this deficiency was reversed in
neutrophils from a CGD patient following gene
therapy [4], supporting the role of NADPH oxidase in
NET generation.CGD: ADisease of Impaired Antimicrobial Host
Defense and Excessive Inflammation
CGDpatients are susceptible to a spectrum of bac-
terial and fungal infections. Patients with the X-linked
CGD appear to be at greater risk for infection and
early mortality compared to patients with autosomal
recessive forms of CGD [1]. In a U.S. registry of 368
patients with CGD, pneumonia was the most frequent
type of infection, occurring in 79% of patients, with
Aspergillus species being the most common cause [1]
(Table 1). Fifty-three percent of patients had suppura-
tive adenitis, 42% had a subcutaneous abscess, and
27% had a liver abscess; Staphylococcus aureus was the
most common cause of soft tissue and liver abscesses.
Twenty-five percent (25%) had osteomyelitis (Serratia
marcescens was the most prevalent cause), and 18% had
sepsis (Salmonella species were the most prevalent
cause). The most common causes of death were pneu-
monia and/or sepsis because of Aspergillus species (23
patients) or Burkholderia cepacia (12 patients). A Euro-
pean registry of 429 CGD patients showed that the
most frequently cultured pathogens per episode were
S. aureus (30%), Aspergillus species (26%), and Salmo-
nella species (16%); Aspergillus species (111 cases)
were the most common cause of pneumonia [6].
In addition to recurrent infections, CGD is also
characterized by abnormally exuberant inflammatory
Table 1. Infections in CGD
Site Most Common Pathogens Diagnostic Methods
Lungs (pneumonia) Aspergillus species and other molds,
B. cepacia, S. aureus, Nocardia species
Sputum culture (least invasive but insensitive for molds); blood
culture (in cases of pneumonia and secondary bacteremia);
bronchoalveolar lavage (BAL) and biopsy; percutaneous lung
biopsy; and thoracoscopic or open lung biopsy. More than one
pathogen can be present.
Lymph nodes (suppurative adenitis) S. aureus Culture
Skin (subcutaneous abscesses;
infected cysts)
S. aureus Culture
Liver (abscesses) S. aureus Culture
Bone (osteomyelitis) S. marcescens Culture
Blood (sepsis) Salmonella species, S. aureus, B. cepacia Culture
CGD indicatres chronic granulomatous disease.
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granulomatous enteritis resembling Crohn’s disease
[7] and genitourinary obstruction. ‘‘Mulch pneumoni-
tis’’ is a recently described life-threatening hyperin-
flammatory response to fungal pneumonia in CGD,
requiring both antifungal therapy and systemic corti-
costeroids [8].
Mouse models of CGD support the notion that
excessive inflammatory responses are not simply the
result of unresolved infection, but rather reflect an
important role of NADPH oxidase in regulating
inflammation. For example, Morgenstern et al. [9]
showed that intratracheal administration of heat-
killed A. fumigatus hyphae elicited mild self-limited
inflammation in wild-type mice, but robust and persis-
tent inflammation in CGD mice. Romani et al. [10]
linked impaired antifungal host defense and excessive
inflammation in CGD mice to defective activation of
tryptophan catabolism and generation of regulatory
T cell responses. Segal et al. [11] showed that CGD
mice and peripheral blood mononuclear cells
(PBMCs) from CGD patients had impaired activation
of Nrf2, a redox-sensitive transcriptional factor that
induces oxidant scavenging pathways and functions
to limit cellular injury and inflammation. These results
support a model in which NADPH oxidase can limit
innate and T cell responses by modulating specific
redox-sensitive pathways.
Care of the CGD Patient
Diagnosis of CGD
The first component in care of the CGD patient is
early diagnosis. CGD should be suspected in patients
with recurrent or unusually severe infections, such as
a liver abscess caused by Staphylococcus aureus. In addi-
tion, specific opportunistic infections should prompt
an evaluation for CGD; these include invasive mold
diseases (eg, aspergillosis), and infections by B. cepacia,
S. marcescens, and Nocardia species in the absence of
a known immunodeficiency. Inflammatory disorders
such as inflammatory bowel disease at an early age
and granulomatous cystitis can be manifestations ofCGD. A family history of males with severe or unusual
infections can be a clue to the diagnosis of X-linked
CGD, whereas consanguineous parents increase the
risk for autosomal recessive disorders.
The diagnosis of CGD requires demonstration of
defective NADPH oxidase activity in neutrophils.
The most common diagnostic assays are the nitroblue
tetrazolium dye reductionmethod (ameasure of super-
oxide anion release) and flow cytometry evaluating di-
hydrorhodamine 123 (DHR) fluorescence (a measure
of intracellular hydrogen peroxide). DHRfluorescence
is likely to be the most sensitive method for diagnosis,
particularly in cases of variant X-linked and autosomal
recessive forms of CGD, where low levels of NADPH
oxidase activity may lead to false-positive results with
the nitroblue tetrazolium method.
Antibiotic and recombinant interferon-g
prophylaxis
CGD patients should receive antibacterial and
mold-active antifungal prophylaxis. Trimethoprim-
sulfamethoxazole is generally the recommended agent
for antibacterial prophylaxis. It is well-tolerated inCGD
patients, and has activity against themajority of bacterial
pathogens encountered in CGD patients: S. aureus
(including the predominant community-acquired strain
ofmethicillin-resistant S. aureus),B. cepacia, andNocardia
species. If trimethoprim-sulfamethoxazole is not feasible
(eg, because of allergy), an antistaphylococcal penicillin
(eg, dicloxacillin) is advised. Given the high risk of
invasive fungal diseases in CGD, mold-active antifungal
prophylaxis is also warranted. Itraconazole was safe
and effective in patients with CGD [12]. Extended-
spectrum azoles (voriconazole and posaconazole) are
alternative agents that can be used as prophylaxis.
In a randomized trial, recombinant interferon-g sig-
nificantly reduced the incidence of serious infections in
patients with CGD [13]. Interferon-g was beneficial re-
gardless of age, the use of prophylactic antibiotics, and
the type of CGD (X-linked or autosomal recessive), and
waswell tolerated.Althoughprior studies showed that in-
terferon-g could augment superoxide production in
phagocytes fromCGDpatients, therewere no significant
S126 Biol Blood Marrow Transplant 17:S123-S131, 2011B. H. Segal et al.changes in the measures of superoxide production by
phagocytes in the randomized trial. Thus, the benefit of
prophylactic recombinant intereferon-g likely results
from augmentation of oxidant-independent pathways.
Diagnosis and treatment of infections
CGD patients may not manifest typical signs of in-
fection. Fever and leukocytosis may be absent, and an
elevated sedimentation rate may be the only abnormal
laboratory test. In a review of aspergillosis in CGD pa-
tients at the National Institutes of Health (NIH), one-
third of patients were asymptomatic at diagnosis, and
only20%were febrile [14]. Inmany of these patients,
a pulmonary infiltrate on routine screening chest X-
ray or computed tomography (CT) scan was the first
indication of an infection. The white blood cell count
was#10,000/mL in 13/23 cases, and the sedimentation
rate was #40 mm per hour in 9/20 cases.
When infections are suspected, it is important to
establish a culture diagnosis when feasible prior to ini-
tiating antimicrobial therapy. Chest CT scans are use-
ful to detect early pneumonia. If noninvasive testing
(eg, blood and sputum cultures) are nondiagnostic,
an invasive procedure should be considered. Serum
galactomannan (a diagnostic marker for invasive asper-
gillosis) appears to be insensitive in CGD patients; this
may be related to the fact that hyphal vascular invasion,
a common feature of invasive aspergillosis in neutro-
penic patients, is generally not observed in invasive
aspergillosis in CGD. A percutaneous lung biopsy is
probably the most useful approach for peripheral
lung lesions. Biopsy material should be submitted for
pathology as well as bacterial and fungal culture, in-
cluding Nocardia. Frequent radiographic evaluation
(eg, chest radiographs during routine clinic visits and
CT scans in patients with fever or focal signs) is critical
to making early diagnoses.
Debridement or resection of infected tissue may be
required. Infections that involve bone or deep soft
tissue are generally most effectively treated with anti-
biotics and surgery. Aspergillus nidulans is associated
with severe infections in CGD patients, frequently
manifesting with extension to the chest wall and verte-
brae, and requiring prolonged therapy in combination
with debridements [14].
Adjunctive granulocyte transfusions have been
used for severe or refractory infections in CGD
patients. Use of granulocyte transfusions in CGD is
supported by the principle that a small proportion of
normal phagocytes may be able to complement the
oxidative defect inCGDphagocytes. Hydrogen perox-
ide generated by normal neutrophils can diffuse into
CGD neutrophils and provide the necessary reagent
to generate hypohalous acid and hydroxyl anion in vi-
tro. Transfused granulocytes retain respiratory burst
activity and appear to traffic normally based on theirrecovery from sites of infection. Granulocyte transfu-
sions are generally well tolerated, but adverse effects
include fevers, development of leukoagglutinins lead-
ing to rapid loss of transfused granulocytes, and rarely,
pulmonary leukostasis. The likelihood of pulmonary
leukostasis may be increased if amphotericin B and
granulocytes are administered concomitantly; there-
fore, granulocyte transfusions and amphotericin B
should be administered several hours apart. Granulo-
cyte transfusions can predispose to alloimmunization,
which is of concern for patients under consideration
for hematopoietic cell transplantation.HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) FOR CGD
HCT provides curative therapy for patients with
CGD, although controversy exists over the requirement
for HCT in all patients, and the optimal timing for any
HCT procedure. Although uncomplicated CGD is not
necessarily an indication for transplantation, HCT
should be considered for CGD patients whose clinical
history demonstrates significant morbidity (recurrent
life-threatening infections, an ongoing infection refrac-
tory to treatment, progressive granulomatous restrictive
lung disease, and/or high-dose steroid-dependent or re-
fractory severe granulomatous colitis). In patients with
these morbidity indicators, nonavailability of specialist
medical care or noncompliance with long-term antimi-
crobial prophylaxis may additionally influence the
decision to transplant [15].
In the largest reported series, 27 patients under-
went HCT for CGD complicated as above in 14 coop-
erating European centers between 1985 and 2000 [16]
(Table 2). Most transplants were in children (n 5 25),
received a myeloablative busulfan-based regimen (n5
23), and had unmodified marrow allografts (n 5 23)
from HLA-identical sibling donors (MSD). Twenty-
three of 27 (85%) survive, with 22/23 survivors cured
of CGD. Preexisting infections and chronic inflamma-
tory lesions cleared in all engrafted survivors, even
children with severe lung restriction profited, slowly
normalizing decreased oxygen saturation and revers-
ing clubbing of fingers and toes. Survival was especially
good in patients without infection at the time of HCT
(18/18), and one could argue that with the availability
of a geno-identical donor, HCT should be performed
in all patients early in life, at a time whenHCT is more
easily tolerated, and prior to the development of
complications that cannot be predicted by laboratory
parameters.With the introduction of in vivo T cell de-
pletion using alemtuzumab excellent outcomes have
also been reported using matched unrelated donors
(MUD) in 9/10 CGD patients undergoing largely
myeloablative HCT [17]; as a consequence, the same
arguments for performing HCT from a sibling donor
Table 2. Summary of HCT Studies for CGD
Study No. Regimen Donor OS EFS
Segar et al. [16] 25 MA MSD 85% 81%
G€ung€or et al. [18,19] 8 RIC MSD/MUD 88% 88%
Veys (personal communication) 5 RIC MUD/MMUD 100% 100%
Horwitz et al. [23] 10 NMA MSD 70% 70%
Kang (personal communicaiton) 11 NMA MSD/MUD 91% 82%
MA indicates myeloablative; RIC, reduced-intensity condition; NMA, nonmyeloablative; MSD, matched sibling donor; MUD, matched unrelated donor;
MMUD, antigen mismatched unrelated donor; OS, overall survival; EFS, event-free survival.
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matched unrelated donor.
In contrast to HCT in the uncomplicated child,
HCT during active infection (eg, aspergillosis) or in-
flammation (eg, colitis) is sometimes complicated by se-
vere inflammatory reactions at the site of infection/
inflammation [16]. Ideally, infections and inflammatory
lesions should be brought under control prior to HCT,
but in chronically infected patients or patients with
ongoing inflammation, morbidity may be reduced by
employing less toxic conditioning regimens and includ-
ing serotherapy with ATG or alemtuzumab. HCT us-
ing reduced-intensity conditioning (RIC) combining
busulfan 8-10 mg/kg (adjusted with busulfan kinetics
in pediatric patients), fludarabine 180 mg/m2, and
ATG 40 mg/kg and matched donors (matched sibling
donor [MSD]5 5, matched unrelated donor [MUD]5
3) was performed in 8 high-risk CGD patients. With
this approach, 90% to 100% donor chimerism was
achieved in all cases at a median follow-up of 26months
[18,19]; this was despite the use of bone marrow rather
than mobilized peripheral blood stem cells (PBSC) in
7/8 cases. Seven patients are alive and well and all
active inflammatory and infectious foci are resolved.
One adult patient who had received PBSC from
a cytomegalovirus (CMV)-negative MUD died on day
1150 of CMV pneumonitis. An alternative RIC
regimen (4 Gy of total-body irradiation [TBI], cyclo-
phosphamide 50 mg/kg, and fludarabine 200 mg/m2)
followed by 2 mismatched unrelated cord blood units
in a single adult McLeod (K0 red cell) phenotype
CGD patient with invasive aspergillosis also resulted
in full donor engraftment and cure [20]. However, all
5 CGD patients who received alemtuzumab and fludar-
abine in combination with melphalan 140 mg/m2 [21]
survived, but sustained donor engraftment was achieved
in only 2/5 (T. Gungor 2008, personal communica-
tion), suggesting that the risk of graft rejection may
be increased in CGD patients with this protocol in
comparison to other phagocytic disorders (Table 2).
Busulfan may also be substituted with treosulfan [22],
and RIC HCT employing Alemtuzumab, treosulfan
42 g/m2 and fludarabine 150 mg/m2 resulted in full
donor chimerism and cure in 5/5 CGD patients under-
going matched or mismatched (single HLA antigen)
unrelated donor HCT with mobilized peripheralblood stem cells (Veys 2010, personal communication)
(Table 2). One of these children undergoing mis-
matched unrelated donor HCT had severe CGD com-
plications prior to HCT including lung and cerebral
aspergillosis, which has resolved completely post-HCT.
Horwitz and colleagues [23] reported 10 patients
withCGDwhounderwentHCTwithminimal intensity
conditioning comprising cyclophosphamide (120 mg/
kg), fludarabine (125 mg/m2), and ATG (160 mg/kg),
followed by transplant of CD341-selected PBSCs
from matched sibling donors (Table 2). Delayed donor
lymphocyte infusions were given at intervals of 30 or
more days to increase the level of donor chimerism.
After a median follow-up of 17 months, donor myeloid
chimerism in 8/10 patients ranged from 33% to 100%,
a level that could be expected to provide normal host de-
fense. In 2 patients, graft rejection occurred. Significant
aGHVDdeveloped in 3 of 4 adult patients with engraft-
ment, 1 of whom subsequently had extensive cGVHD.
Seven patients were reported to have survived from 16
to 26 months. Two patients died of transplant-related
complications.
In an ongoing transplant study initiated in late
2007 at the NIH (E.M. Kang and colleagues, personal
communication), 11 patients with CGD have been
transplanted using a nonmyeloablative regimen of
busulfan plus Campath or ATG, along with low-dose
radiation for those receiving an unrelated donor prod-
uct (Table 2). High-dose sirolimus is used as GVHD
prophylaxis. Two have had HLA matched sibling do-
nors; 8 have received matched unrelated PBSC grafts;
and 1 has had an unrelated cord blood. Of particular
note is that 9 of the 11 patients had ongoing refractory
infections, all of which are improving or have resolved
following successful transplant. There has been 1
death (preexisting renal failure unrelated to the trans-
plant), only 1 graft failure (the cord blood), and only 1
Grade 2 or higher GVHD (Grade 2, skin only).
In the absence of a matched sibling or closely
matched unrelated donor ($7/8 HLA antigens), hap-
loidentical or mismatched cord (\5/6 HLA antigens)
HCT have been attempted but are probably too risky.
In at least 1 reported case of a high-risk CGD patient,
the family resorted to preimplantation genetic diagno-
sis and HLA typing to create a ‘‘savior sibling’’ for suc-
cessful HCT of a brother suffering from X-CGD [24].
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proach is not typically covered by third-party payers,
and thus is not readily available to the general popula-
tion. An alternative approach would be to pursue stem
cell gene therapy (see below).
In conclusion, myeloablative HCT using a closely
matched related or unrelated donor is a valid therapeu-
tic option for children with CGD if performed early in
life or at the first signs of a severe course of the disease.
The use of RIC HCT awaits further evaluation, but
combinations of ATG/busulfan/fludarabine or Alem-
tuzuab/treosulfan/fludarabine appear to be particu-
larly suitable for high-risk patients with CGD, and
may eventually be utilized in more standard-risk pa-
tients if long-term donor myeloid engraftment can
be secured.DEVELOPMENTOF GENE THERAPY
FOR CGD
Among the first uses of gene therapy formonogenic
disorders that demonstrated unequivocal substantial
long-term clinical benefit were for 2 forms of severe
combined immune deficiency, SCID-X1 (caused by
mutations in the IL2RGgene) andADA-SCID (caused
by mutations in the gene encoding adenosine deami-
nase). The approaches taken to achieve successful
gene therapy for SCID-X1 and ADA-SCID, and the
problems encountered have had a substantial impact
on informing the past and ongoing initiatives to de-
velop clinically beneficial gene therapy for CGD.
The first clinical trial of gene therapy for CGD
occurred in 1995 and was directed toward young adult
CGD patients with the p47phox-deficient autosomal
recessive form of CGD [25]. The MFGS gene transfer
vector (derived from murine Moloney leukemia virus)
encoding p47phox cDNA was used to transduce
peripheral blood1/Nmobilized autologous CD341
cytokine–mobilized peripheral blood stem cells (PBSC)
in a 4-day culture. Five patientswere treatedwith a single
cycle of gene therapy without any chemotherapy condi-
tioning. Most received .0.5  106 transduced autolo-
gous CD341 cells/kg. Based on the dihydrorhodamine
flow cytometry (DHR) assay to measure reactive oxygen
species (ROS) in individualneutrophils [26], all 5patients
had the appearance of\1:2000 oxidase normal neutro-
phils in the peripheral blood. Trace numbers of
oxidase-normal neutrophils persisted for only a few
months, and no clinical benefit was demonstrated. This
trial pioneered the first clinical use of a closed system
of gas-permeable flexible plastic bags for culture and
transduction of CD341 hematopoietic stem cells
(HSCs) [27].
In 1998, a clinical trial of similar design was initi-
ated at the NIH, also without conditioning, using
the same MFGS retrovirus vector backbone encoding
gp91phox and autologous CD341 PBSC to treat 5older teenage or young adult patients with X-linked
CGD (X-CGD) [28]. The much higher titer of vector
and the application of Retronectin (fibronectin frag-
ment) coating of the inner surface of the culture bags
resulted in ex vivo transduction efficiencies of .60%.
Furthermore, patients received 1-4 cycles of treatment
of.10  106 transduced autologous CD341 cells/kg/
cycle. Most patients had transient appearance of up to
1:900 oxidase normal neutrophils, which persisted in
the circulation for only a few months with equivocal
clinical benefit. Despite extraordinarily high bulk
transduction rates and the large number of transduced
autologous CD341PBSC infused, genemarking never
exceeded 0.2%. However, the individual gene-marked
neutrophils in the circulation appeared to produce
normal levels of ROS. Thus, the critical problem ap-
peared to be that in the absence of bone marrow con-
ditioning, circulating gene-corrected neutrophils were
very low and transient.
Concordant with this second CGD clinical trial,
investigators in France had begun to treat infants
with SCID-X1 using a very similar MFG vector back-
bone encoding the IL2RG gene cDNA to transduce
bone marrow CD341 HSCs [29]. Despite the facts
that the culture and transduction conditions for the
SCID-X1 trial were similar to those in the 2 CGD tri-
als, that rates of bulk ex vivo transduction averaged
only 40%, that the number of transduced HSCs in-
fused were less than in the second CGD trial, that
the SCID-X1 infants received only a single cycle of
treatment, and that no conditioning was given, the
clinical results were spectacularly better. The great
majority of treated SCID-X1 infants developed nor-
mal numbers of functionally corrected T lymphocytes.
There was some production of functionally normal B
lymphocytes and even detection of some NK cells
for a period of time. Investigators in London con-
firmed these results in a second trial [30]. The general
consensus for why there was such a successful outcome
with SCID-X1 is that the substantially ‘‘empty’’ T lym-
phocyte compartment in SCID-X1 provides a setting
where gene-corrected T lymphocytes, with no compe-
tition from host T lymphocytes, have no barrier to
peripheral growth and can expand to fill this empty he-
matologic niche. For B lymphocytes, the hematologic
niche occupied by this cell type is not ‘‘empty,’’ as it is
occupied by B cells that cannot mature to produce an-
tibody, suggesting why the correction of B cell immu-
nity in SCID-X1 is substantially less than for T cell
immunity. Even this cannot be the full explanation be-
cause these investigators found a persistent modest
level of gene marking in the myeloid compartment of
the infants where there should be no selective growth
advantage. One can speculate that infants likely have
a highmarrow turnover rate that additionally facilitates
substantially more efficient engraftment of gene-
marked autologousHSCs than older children or adults.
Figure 2. Dihydrorhodamine flow cytometry dot-plot analysis of oxi-
dase activity in phorbol ester–stimulated circulating blood neutrophils of
a patient in the NIH study with X-CGD who had busulfan conditioning
followed by infusion of autologous CD341 HSC transduced with MFGS-
gp91phox vector 3 years and 9 months prior to this analysis. The analysis
is gated to showonly neutrophils where Y-axis is side-scatter and X-axis is
fluorescence intensity. Note that the 0.8% of neutrophils producing ROS
has intensity of fluorescence equal to that seen in normal neutrophils.
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tial immune reconstitution in the Paris and London
gene therapy studies, 5 have had vector insertional
mutagenesis-associated clonal lymphocytic leukemia
[31,32]. This has raised concerns about the safety of the
genome insertion pattern of murine retrovirus vectors,
and in particular, about the potential activation of
nearby proto-oncogenes from this type of vector’s long
terminal repeat (LTR).
One of the earliest series of clinical trials of ex vivo
gene therapy beginning in the early 1990s was the at-
tempted treatment of children with ADA-SCID
[33,34]. Although there was prolonged gene marking,
possibly some improvement of immune function, and
possible clinical benefit, none of the patients achieved
a profound outgrowth of gene-corrected T lympho-
cytes, substantial improvements in immune function,
or significant clinical benefit. In 2002, investigators
from Italy reported the results of a clinical trial of gene
therapy for ADA-SCID that did achieve significant
immune reconstitution and clinical benefit by using
nonmyeloablative conditioning with low-dose busulfan
(4mg/kg total) prior to infusionofgene-corrected autol-
ogousCD341HSCs [35]. Thiswas a critical conceptual
breakthrough demonstrating that in settings where
selective growth advantage is less evident, marrow con-
ditioning to enhance engraftment of gene-corrected
HSC can substantially improve the clinical outcome.
These investigators also withheld enzyme replacement
therapy with PEG-conjugated ADA in order to further
enhance the growth advantage of gene-corrected cells
[36].These resultswere confirmedby studies inLondon
and the United States [37]. To date, no vector insertion
mutagenesis–related adverse events have been seen in
the nearly 20 ADA-SCID patients treated with murine
retrovirus gene therapy.
Gene correction for CGD should not provide any
growth advantage either within the stem cell or mye-
loid compartments affected by the immune defect.
Borrowing the lesson about conditioning from the
ADA-SCID experience, investigators in Germany
initiated a clinical trial of ex vivo gene therapy for
X-CGD that incorporated nonmyeloablative condi-
tioning with a higher dose of busulfan (8 mg/kg total)
to treat 2 adults [38]. They used retrovirus vector de-
rived from murine spleen focus forming virus (SFFV
vector) encoding the human gp91phox cDNA to trans-
duced autologous CD341 PBSC, achieving about
40% transduction efficiency. Initially, there was 20%
to 30% gene marking with significant levels of ROS
activity in circulating neutrophils. Unexpectedly, the
level of gene-corrected neutrophils increased over 6
months until gene-marked neutrophils comprised
more than half of the circulating neutrophils. How-
ever, this temporal increase in gene marking was asso-
ciated with oligoclonal expansion. The predominant
clone in both patients had the vector inserted intoMDS1/EVI1, where activation of this gene was likely
responsible for the expansion. Initially, this benefited
these patients in that their infections cleared. How-
ever, over the next 2-1/2 years, both patients developed
myelodysplasia with monosomy 7 and loss of oxidase
function in the gene-marked myeloid cells (silencing),
although with persistence of activity of the SFFV
enhancer sequence [39]. One patient died of severe
sepsis likely related to the myelodysplasia, whereas
the other was successfully treated with an allogeneic
HSC transplant. Subsequently, a child with X-CGD
achieved cure of a severe infection following gene
therapy with the same SFFV vector, but without oligo-
clonal or clonal expansion [4]. Nonetheless, concern
for the safety of the SFFV vector has been raised.
In 2006, the NIH group used the same MFGS-
gp91phox vector to treat X-CGD as in their
1998-2001 study, but used conditioning with nonmye-
loablative busulfan (10 mg/kg total) before infusing the
transduced autologousCD341HSC [40]. Interestingly,
1 patient in this trial previously had been treated in the
1999 trial with the same vector but without condition-
ing, affording an opportunity to evaluate the efficacy
of busulfan conditioning. In 1999, this patient achieved
gene marking of1:1500 (0.75%) circulating neutro-
phils, and the marking became undetectable after a few
months. In 2006, this patient achieved gene marking
of 24%of all circulatingneutrophils at 3weeks postinfu-
sion. This decreased to10%by 3months and to1%
Figure 3. Candidate clinical insulated self-inactivating lentivirus vector
plasmid pCL20i4r-EF1a-gp91OPT under development for treatment of
X-CGD (HL Malech, EM Kang, U Choi, SS De Ravin, BP Sorrentino,
RE Throm, and JT Gray, unpublished data). Shown is the vector plasmid
indicating that gag and pol and the 30 LTR all have inactivating deletions;
tat, rev, env, and other elements have been removed; 400-bp portion of
the chicken H4 globin insulator has been added (CI); a short version of
the human Elongation factor 1 alpha has been added as the internal pro-
moter; and the gp91phox cDNA has been codon optimized (gp91OPT).
The structure is based upon the vector described by Zhou et al. [44]. A
producer cell line is also being developed based upon what is described
in Throm et al. [45].
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circulating neutrophils in this patient are marked at al-
most 4 years after gene therapy (Figure 2). Of particular
note is that the individual gene-marked neutrophils still
demonstrate normal productionofROSwithout any ev-
idence for silencing. An important conclusion from this
study and theCGDstudy fromGermany is thatbusulfan
8-10 mg/kg is likely adequate to achieve the necessary
level of engraftment of gene-transducedHSC to correct
a disorder such as CGD where there is no selective
growth advantage in gene-corrected cells. The critical
need is to find a vector with a high safety profile and
improved transduction efficiency of HSC.
Most of the current gene therapy research focus for
CGD is on lentivirus vectors because they may have
a safer pattern of preferred insertion sites than murine
retrovirus vectors. More important, lentivectors are
more easily designed to incorporate 30 LTR deletions
resulting in self-inactivation of the LTR at the 50 end
following insertion into the genome of the target cell
[41]. This self-inactivating structure of the current
generation of lentivectors may be intrinsically safer
with respect to insertional mutagenesis-mediated
adverse events than the standard murine retrovirus
vectors. However, more clinical experience with self-
inactivating lentivirus vectors is necessary.
The recent report of clinically beneficial functional
correction of X-linked adrenoleukodystrophy with
high-level persistent gene marking of myeloid cells us-
ing a lentivirus vector provides compelling evidence
that they may result in intrinsically higher levels of
gene transfer intoHSC [42]. Furthermore, in the adre-
noleukodystrophy study, myeloablative conditioning
was used, and some have concluded that for future
gene therapy trials for disorders with no intrinsic selec-
tive growth advantage conferred by gene correction,
for example, CGD, that not only should lentivectors
be used, but that myeloablative conditioning is neces-
sary. The counterargument is that CGD patients who
are candidates for gene therapy likely have ongoing in-
fections, making use of ablative conditioning an unac-
ceptable risk; and that previous trials of gene therapy
for CGD suggest that subablative conditioning may
be sufficient. In addition, the use of myeloablative che-
motherapy and resulting increase in early and late side
effects reduces at least some of the attraction of the
gene theapy approach compared to allogeneic HCT.
Self-inactivating lentivectors require the construct
to have an internal promoter to drive production of the
therapeutic transgene. The strongest internal pro-
moters are virus promoters, but for safety reasons, an
adequately functioning mammalian gene promoter is
preferable for CGD. This is problematic in designing
lentivectors for X-CGD because most mammalian in-
ternal promoters to date are not sufficiently active to
drive adequate production of gp91phox from the
transgene to achieve functional correction of gene-marked X-CGD neutrophils. Codon optimization of
the gp91phox cDNA seems to help [43], but this alone
is insufficient. Current effort in lentivector develop-
ment for X-CGD is focused on finding the best inter-
nal promoter to achieve functional correction of the
gene-marked neutrophil. An example of a candidate
lentivector under development to treat X-CGD is
shown in Figure 3.ACKNOWLEDGMENTS
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